HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A new drug for an old bug.

Abstract
There is an urgent need to develop new drugs for the treatment of tuberculosis, particularly against latent/persistent forms of the causative agent, Mycobacterium tuberculosis. In this issue of Chemistry & Biology, Krieger and colleagues use a structure-guided approach to develop novel inhibitors of malate synthase, a target in the glyoxylate shunt that is critical for pathogen survival in chronic infection.
AuthorsPeter J Myler, Robin Stacy
JournalChemistry & biology (Chem Biol) Vol. 19 Issue 12 Pg. 1499-500 (Dec 21 2012) ISSN: 1879-1301 [Electronic] United States
PMID23261593 (Publication Type: Comment, Journal Article, Research Support, N.I.H., Extramural)
CopyrightCopyright © 2012 Elsevier Ltd. All rights reserved.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: